DermaSensor has received Class IIb CE mark approval for its AI-powered skin cancer assessment device, enabling commercialisation across the European Economic Area.
The handheld device uses elastic scattering spectroscopy and artificial intelligence to assess suspicious skin lesions at the point of care. It is intended for use by qualified healthcare professionals to inform whether a lesion may require further clinical care, including dermatology referral or biopsy.
The CE mark supports DermaSensor’s international expansion after earlier US regulatory clearance. The company is now seeking to work with European commercial partners, healthcare systems, and physician groups to support adoption of the technology.
DermaSensor has also announced a feasibility study with the UK’s National Health Service. The study will evaluate AI-assisted skin cancer assessment when used by GPs in an NHS setting, with further details expected to follow. The company has also entered a commercial partnership with a European distributor, which has invested $5 million in its recent Series B financing.
The device captures non-invasive tissue information using hundreds of wavelengths of light. Its AI-powered system provides an immediate result that supports clinical decision-making. The company says the device has been evaluated across multiple published studies involving clinical sites and clinicians in primary care and dermatology.
Healthcare systems are trying to move more diagnostic activity closer to primary care while managing specialist capacity. Dermatology pathways are often constrained by referral volumes, workforce limits, and the challenge of separating lower-risk lesions from cases that need faster specialist attention. A point-of-care assessment tool does not replace clinical judgement, but it can support triage where access to specialists is limited.
The device also reflects the growing convergence of medical hardware, AI software, optics, electronics, and regulated manufacturing. AI-enabled diagnostics are not simply software products. They require sensor hardware, algorithms, clinical evidence, usability controls, cybersecurity, quality systems, regulatory submissions, post-market surveillance, and manufacturing processes capable of producing consistent devices.
Scaling that type of product is demanding. A device used in front-line healthcare has to be reliable, repeatable, easy to operate, and clinically useful. It also has to fit into workflows that are already stretched. Primary care settings leave little room for tools that add training burden, data complications, or appointment complexity without improving decisions.
The NHS feasibility study will test deployment as much as technical performance. Adoption will depend on clinical protocols, training, reimbursement, patient communication, data governance, and integration with existing referral pathways. The device may provide immediate assessment output, but the healthcare system still has to decide how that output should be used.
Medical device manufacturing is moving towards more connected and digitally enabled products. Sensors, AI algorithms, cloud services, device updates, cybersecurity, and clinical data pathways increasingly sit inside one regulated product ecosystem. That creates opportunities for faster assessment and improved access, while raising expectations for lifecycle management across hardware, software, and clinical performance.
Broader medical manufacturing investment is already moving in the same direction, with automated medical machining capacity and expanded diabetes device consumables production both showing how healthcare demand is pushing manufacturers to scale regulated output while preserving precision and quality.
European market access gives DermaSensor a larger commercial opportunity, but adoption will vary by healthcare system. Procurement processes, clinical pathways, reimbursement structures, and post-market expectations differ across countries. Commercial partners will need to show that the device improves workflow and clinical decision-making, not only that it has cleared regulatory approval.
The CE mark is still a substantial milestone for AI-enabled diagnostic hardware. Skin cancer assessment is a high-volume clinical challenge, and earlier identification remains central to outcomes. If DermaSensor can demonstrate practical deployment in primary care and dermatology pathways, its device could become part of a wider move towards regulated point-of-care technologies that distribute diagnostic support more efficiently across healthcare systems.
